Citadel’s Quiet Drug Fix

The hedge fund firm has been quietly making private investments in biopharma.

Ken Griffin at the Delivering Alpha conference. (Heidi Gutman/CNBC)

Ken Griffin at the Delivering Alpha conference.

(Heidi Gutman/CNBC)

When you think of hedge fund firms that invest in private companies, technology-oriented firms like Tiger Global Management and Coatue Management come to mind, right? And when it comes to biopharmaceutical companies, Perceptive Advisors and Deerfield Management are known investors.

Meanwhile, hedge fund titan Ken Griffin’s Citadel has stayed below the radar in private investing.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related